None
Quote | Marizyme Inc (OTCMKTS:MRZM)
Last: | $0.05 |
---|---|
Change Percent: | 0.0% |
Open: | $0.05 |
Close: | $0.05 |
High: | $0.05 |
Low: | $0.05 |
Volume: | 11,499 |
Last Trade Date Time: | 07/16/2024 03:00:00 am |
News | Marizyme Inc (OTCMKTS:MRZM)
JUPITER, FL - ( NewMediaWire ) - May 06, 2024 - Marizyme, Inc. (OTCQB: MRZM) is pleased to announce that its flagship product DuraGraft ® will no longer require refrigerated storage and will be able to be stored at controlled room temperatures of 20 o C-25 o C allowing it to be ...
JUPITER, FL - ( NewMediaWire ) - April 16, 2024 - Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN ) to advance the commercial...
Message Board Posts | Marizyme Inc (OTCMKTS:MRZM)
Subject | By | Source | When |
---|---|---|---|
This has been getting loaded on the #BUYS | Kilmal | investorshub | 06/28/2022 12:28:20 AM |
KokeFischer | investorshub | 08/11/2020 11:26:36 PM | |
According to the latest 8k.... it | Kilmal | investorshub | 01/13/2020 10:29:39 PM |
Wow, that's nice to hear! Where do u | Stallion4life38 | investorshub | 12/18/2019 2:56:34 PM |
This will be a huge money maker, solid | HokieHead | investorshub | 12/17/2019 7:05:00 PM |
News, Short Squeeze, Breakout and More Instantly...
JUPITER, FL - ( NewMediaWire ) - May 06, 2024 - Marizyme, Inc. (OTCQB: MRZM) is pleased to announce that its flagship product DuraGraft ® will no longer require refrigerated storage and will be able to be stored at controlled room temperatures of 20 o C-25 o C allowing it to be ...
JUPITER, FL - ( NewMediaWire ) - April 16, 2024 - Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN ) to advance the commercial...
--News Direct-- Marizyme Inc CEO David Barthel joined Steve Darling from Proactive to provide an exciting update on the remarkable progress that the company has achieved in recent months. Among the standout developments is the approval received from the US Food and Drug Administration for...